Therefore, we undertook this phase 1b/2 study to determine if the combination of binimetinib with nivolumab or nivolumab and ipilimumab could improve outcomes for these patients, as the combination of MEK inhibition with ICI therapy has shown evidence of tumor regression even where either agent alone was only modestly effective [14, 23–25]. Here, MAP2K7 is linked to neoplasm.